Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T16:34:02.758Z.
Calculation as of: 2026-10-06T16:34:02.758Z.
Quote observation: 2026-10-06T16:30:36.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 23d17170dcd90d56222e16e6e1c46ca5d6e49f0f5e08d353dc7d5f06f7b1586d
PEG RATIO
N/A
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vaxcyte, Inc. (PCVX) | $9.51B | N/A | N/A | N/A | N/A |
| Insulet Corp. (PODD)vs › | $9.39B | 0.25 | 0.59 | 0.53 | 0.53 |
| Bruker Corporation (BRKR)vs › | $9.29B | N/A | 1.30 | 1.52 | 2.14 |
| Henry Schein, Inc. (HSIC)vs › | $9.71B | 7.86 | 7.70 | 5.62 | 3.64 |
| Krystal Biotech, Inc. (KRYS)vs › | $9.71B | N/A | N/A | N/A | N/A |
| Bruker Corporation (BRKRP)vs › | $9.00B | N/A | N/A | N/A | N/A |
| Axsome Therapeutics, Inc. (AXSM)vs › | $8.99B | N/A | N/A | N/A | N/A |
| Protagonist Therapeutics, Inc. (PTGX)vs › | $8.88B | N/A | N/A | N/A | N/A |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $9.98B | N/A | 0.04 | 0.21 | 0.23 |
| Repligen Corporation (RGEN)vs › | $10.01B | N/A | 11.12 | 4.92 | 8.39 |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
